Clazosentan in Aneurysmal Subarachnoid Hemorrhage

ClinicalTrials.gov ID: NCT00940095

Public ClinicalTrials.gov record NCT00940095. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 22, 2026, 12:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Prospective, Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Clazosentan in Reducing Vasospasm-related Morbidity and All-cause Mortality in Adult Patients With Aneurysmal Subarachnoid Hemorrhage Treated by Endovascular Coiling.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The aim of this study is to demonstrate that clazosentan, administered as a continuous intravenous infusion at either 5 mg/h or 15 mg/h until Day 14 post aneurysmal subarachnoid hemorrhage (aSAH), reduces the incidence of cerebral vasospasm-related morbidity and all-cause mortality within 6 weeks post-aSAH treated by endovascular coiling. The primary endpoint of the study is the occurrence of cerebral vasospasm-related morbidity, and mortality of all-causes within 6 weeks post-aSAH, defined by at least one of the following: 1. Death (all causes). 2. New cerebral infarct(s) due to cerebral vasospasm as either the primary or relevant contributing cause, or not adjudicated to be entirely due to causes other than vasospasm. 3. Delayed ischemic neurological deficit (DIND) due to cerebral vasospasm as either the primary or relevant contributing cause, or not adjudicated to be entirely due to causes other than vasospasm. 4. Administration of a valid rescue therapy in the presence of confirmed cerebral vasospasm on angiography (DSA or CTA). An independent Critical Events Committee (CEC) will adjudicate whether or not patients meet the primary endpoint and its individual morbidity components.

Study identification

NCT ID: NCT00940095
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 3
Lead sponsor: Idorsia Pharmaceuticals Ltd.; Industry
Enrollment: 577 participants

Conditions and interventions

Conditions

Aneurysmal Subarachnoid Hemorrhage

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years to 75 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 1, 2009 (Type not available)
Primary completion: Oct 1, 2010 (Actual)
Completion: Jan 1, 2011 (Actual)
Last update posted: Jul 9, 2018

2009 – 2011

United States locations

U.S. sites: 29
U.S. states: 19
U.S. cities: 24

Facility	City	State	ZIP	Site status
Glendale Adventist Medical Center	Glendale	California	91206	—
UCSF Medical Centre	San Francisco	California	94143	—
Stanford Hospital and Clinis	Stanford	California	94305-5327	—
Colorado Neurological Institute	Englewood	Colorado	80110	—
Yale Univerity School of Medicine	New Haven	Connecticut	06510	—
University of South Florida	Tampa	Florida	33606	—
Rush University Medical Center	Chicago	Illinois	60612	—
University of Illnois	Chicago	Illinois	60612	—
Massachusetts General Hospital	Boston	Massachusetts	02114	—
Boston Medical Centre	Boston	Massachusetts	02118	—
William Beaumont Hospital	Royal Oak	Michigan	48073	—
Mayo Clinic	Rochester	Minnesota	55905	—
Barnes_Jewish Hospital	St Louis	Missouri	63110	—
Capital Health System Inc. d/b/a The Stroke and Cerebrovascular Center of New Jersey	Trenton	New Jersey	08638	—
Columbia University Medical Center	New York	New York	10032	—
New York Presbyteruan Hospital - Weill Cornell Medical Centre	New York	New York	10065	—
State University of New York at Stony Brook	Stony Brook	New York	11794-8122	—
Duke University Medical Center	Durham	North Carolina	27710	—
University of Cincinnati	Cincinnati	Ohio	45219	—
University Hospitals Case Medical Center	Cleveland	Ohio	44106	—
Oklahoma University Health Sciences Center	Oklahoma City	Oklahoma	73104	—
Oregon Health & Science University	Portland	Oregon	97219	—
Thomas Jefferson University School of Medicine	Philadelphia	Pennsylvania	19107	—
Temple University Hospital	Philadelphia	Pennsylvania	19140	—
Medical University of South Carolina	Charleston	South Carolina	29425	—
University of Texas Southwestern Zale Lipshy Hospital	Dallas	Texas	75390	—
Univ. of VA Health System	Charlottesville	Virginia	22908	—
Virginia Commonwealth University Medical Centre	Richmond	Virginia	23284	—
Virginia Commonwealth University	Richmond	Virginia	980631	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 116 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00940095, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 9, 2018 · Synced Oct 22, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00940095 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →